10:07 AM EST - Intellipharmaceutics International Inc. : announced that the Company and Par Pharmaceutical, Inc. have added the development and commercialization of additional strengths of generic Focalin XR(R) (dexmethylphenidate hydrochloride) for the U.S. market to their existing agreement, which applied to the development and commercialization of the 5-, 10-, 15- and 20-mg strengths of generic Focalin XR. Intellipharmaceutics International Inc.
shares T.I are trading even at $2.85.
